{"id":"https://openalex.org/G19486757","display_name":"Immunological response against bone and soft tissue sarcoma","description":"We performed phase I clinical peptide vaccination trial for patient with osteosarcoma. We used HLA-A24 or HLA-A2-restricted PBF-derived peptides as the vaccines with incomplete Freund' adjuvant. The peptide-specific CTL responses were observed in two HLA-A24+ and one HLA-A2+patients. After the confirmation of safety and immunogenicity of the peptide vaccines, we will plan phase II trial as adjuvant therapy after operative resection combined with post-operative chemotherapy.In addition, we generated artificial antibody against HLA/peptide complex recognized by CTL(natural epitope antibody). scFv phage display library was constructed from RNA derived from human naive PBMC and tonsiles, followed by biopanning using HLA-A2/PBF peptide complex. After panning, one scFv clone was obtained and converted into hIgG1 subtype(scFv-hIgG1). The scFv-hIgG1 recognized peptide-pulsed T2 cells by FACS and showed high affinity by SPR analysis. This natural epitope antibody might be useful for the detection of HLA/peptide complex on tumor cells and for the development of genetically engineered CTLs expressing natural epitope antibody for adoptive cell therapy.","funder_award_id":"22689041","funder":{"id":"https://openalex.org/F4320334764","display_name":"Japan Society for the Promotion of Science","doi":"https://doi.org/10.13039/501100001691"},"funded_outputs":["https://openalex.org/W1533392829","https://openalex.org/W1971226311","https://openalex.org/W2063718836","https://openalex.org/W2107431303","https://openalex.org/W2116030280"],"funded_outputs_count":5,"parent_awards":[],"sub_awards":[],"sub_awards_count":0,"amount":25610000.0,"currency":"JPY","amount_usd":null,"amount_usd_basis":null,"recipients":[],"recipient_countries":[],"recipient_regions":[],"research_scope":{"is_research":true,"basis":"funder_default","tier":1},"funding_type":"fellowship","funder_scheme":"Grant-in-Aid for Young Scientists (A)","start_date":null,"end_date":null,"start_year":null,"end_year":null,"landing_page_url":"https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-22689041/","doi":null,"provenance":"kaken","lead_investigator":{"given_name":"Tomohide","family_name":"TSUKAHARA","orcid":null,"role_start":null,"affiliation":{"name":"Sapporo Medical University","country":"Japan","ids":[{"id":"https://nrid.nii.ac.jp/nrid/1000020404634","type":"nrid","asserted_by":"kaken"}]},"author":{"id":"https://openalex.org/A5000123851","display_name":"Tomohide Tsukahara","orcid":"https://orcid.org/0000-0002-3678-4359"},"institutions":[{"id":"https://openalex.org/I141882310","display_name":"Sapporo Medical University","ror":"https://ror.org/01h7cca57","country_code":"JP","type":"education","lineage":["https://openalex.org/I141882310"]}]},"co_lead_investigator":null,"investigators":null,"works_api_url":"https://api.openalex.org/works?filter=awards.id:G19486757","primary_topic":{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.9932,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.9932,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12576","display_name":"vaccines and immunoinformatics approaches","score":0.0042,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0006,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/osteosarcoma","display_name":"osteosarcoma","score":0.924},{"id":"https://openalex.org/keywords/bone-and-soft-tissue-sarcoma","display_name":"bone and soft tissue sarcoma","score":0.817},{"id":"https://openalex.org/keywords/peptide-vaccination","display_name":"peptide vaccination","score":0.784},{"id":"https://openalex.org/keywords/hla-a24","display_name":"HLA-A24","score":0.887},{"id":"https://openalex.org/keywords/hla-a2","display_name":"HLA-A2","score":0.969},{"id":"https://openalex.org/keywords/ctl-response","display_name":"CTL response","score":0.602},{"id":"https://openalex.org/keywords/incomplete-freund-s-adjuvant","display_name":"incomplete Freund's adjuvant","score":0.933},{"id":"https://openalex.org/keywords/scfv-phage-display","display_name":"scFv phage display","score":0.672},{"id":"https://openalex.org/keywords/hla-peptide-complexes","display_name":"HLA-peptide complexes","score":0.771},{"id":"https://openalex.org/keywords/adoptive-immunotherapy","display_name":"adoptive immunotherapy","score":0.773},{"id":"https://openalex.org/keywords/tumor-immunology","display_name":"tumor immunology","score":0.398}],"sustainable_development_goals":[{"score":0.9858,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"institution_awarded":[{"id":"https://openalex.org/I141882310","display_name":"Sapporo Medical University","ror":"https://ror.org/01h7cca57","country_code":"JP","type":"education","lineage":["https://openalex.org/I141882310"]}],"updated_date":"2026-11-13T03:01:57.000Z","created_date":"2026-07-13T04:17:19.000Z"}